Literature DB >> 9879692

Part I. Telomerase levels in human metastatic brain tumors show four-fold logarithmic variability but no correlation with tumor type or interval to patient demise.

B K Kleinschmidt-DeMasters1, A L Shroyer, T L Hashizumi, L C Evans, N Markham, G Kindt, K R Shroyer.   

Abstract

Telomerase expression has been found in the majority of human neoplasms at their primary sites and, in some tumor types, has been correlated with patient prognosis. In part one of this two-part study, we investigated whether telomerase was expressed ubiquitously in metastases to the brain and whether varying levels of expression existed or correlated with patient prognosis. A second aim of this study was to acquire data on brain metastases preliminary to the investigation of whether the telomerase assay could be used for the detection of tumor cells in cerebrospinal fluid (CSF). We investigated 35 brain metastases utilizing the sensitive telomeric repeat amplification protocol (TRAP) assay coupled with densitometric quantitation of telomerase levels on frozen, banked tissue specimens. Specimens metastatic to the brain analyzed in this study included melanoma, adenocarcinoma, hepatocellular carcinoma, germ cell neoplasm, squamous cell carcinoma, osteogenic sarcoma, and secondary lymphoma. Telomerase was found in 32 of 35 metastases. Quantitation of the telomerase products showed a fourfold logarithmic variation, following standardization of protein concentrations. Levels of telomerase expression showed no statistical correlation with either tumor subtype or interval from date of procedure to patient demise. Interestingly, in two patients with two metastatic samples each taken at discordant times, the telomerase levels were higher in the metastasis specimen taken closer to the time of demise. This suggests a possible increase in telomerase level within a given patient's neoplasm as the disease became more advanced, although too few cases were available to reach a firm conclusion in this regard. We conclude that most brain metastases express telomerase, albeit at widely varying levels, which are not clearly correlated with patient survival. These results influence the potential utility of telomerase analysis for the detection of small numbers of metastatic tumor cells in CSF, as addressed in the companion manuscript.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9879692     DOI: 10.1016/s0022-510x(98)00253-6

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  4 in total

1.  Brain metastases from hepatocellular carcinoma in US patients.

Authors:  Joshua Seinfeld; Aaron Scott Wagner; B K Kleinschmidt-DeMasters
Journal:  J Neurooncol       Date:  2006-01       Impact factor: 4.130

Review 2.  Adenoviral vectors for prodrug activation-based gene therapy for cancer.

Authors:  Joshua C Doloff; David J Waxman
Journal:  Anticancer Agents Med Chem       Date:  2014-01       Impact factor: 2.505

3.  Prognostic implication of telomerase activity in patients with brain tumors.

Authors:  Choong Hyun Kim; Jin Hwan Cheong; Koang Hum Bak; Jae Min Kim; Suck Jun Oh
Journal:  J Korean Med Sci       Date:  2006-02       Impact factor: 2.153

4.  mRNA quantification and clinical evaluation of telomerase reverse transcriptase subunit (hTERT) in intracranial tumours of patients in the island of Crete.

Authors:  A Yannopoulos; E Dimitriadis; A Scorilas; T Trangas; E Markakis; M Talieri
Journal:  Br J Cancer       Date:  2005-07-11       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.